November 3 deadline set for Beta Bionics securities litigation
Investors who purchased Beta Bionics stock between mid-2025 and early 2026 face a November 3, 2026, deadline to seek lead plaintiff status in an ongoing class action lawsuit.
A class action lawsuit is currently proceeding against Beta Bionics regarding allegations of material misrepresentations concerning its iLet automated insulin delivery system. Rosen Law Firm has issued a notice reminding investors who purchased common stock between July 30, 2025, and February 24, 2026, of the upcoming deadline to apply to lead the litigation.
The complaint alleges that Beta Bionics concealed critical issues raised by the FDA regarding device malfunctions. Specifically, the suit claims the company misrepresented the severity of thousands of reports indicating that the iLet device caused dangerously high insulin levels in patients. The lawsuit contends that the company failed to take meaningful corrective action after these incidents were brought to light.
Investors who purchased shares during the class period are not required to take immediate action, as no class has yet been certified. Individuals may choose to retain their own counsel or remain absent members of the class while the litigation proceeds toward the November deadline for lead plaintiff selection.